ArticleOncogene2005
Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Elastic transformation of histological slices allows precise co-registration with microCT data sets for a refined virtual histology approach.Scientific reports · 2021Article
- Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.The Journal of clinical investigation · 2017Article
- T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.Oncotarget · 2016Article
- eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells.Cancer research · 2015Article
- TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.International journal of oncology · 2015Article
- OncomorphicJournal of cancer therapy · 2014Article
- Modeling human protein aggregation cardiomyopathy using murine induced pluripotent stem cells.Stem cells translational medicine · 2013Article
- Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development.Journal of cellular and molecular medicine · 2013Review
- A site-specific recombinase-based method to produce antibiotic selectable marker free transgenic cattle.PloS one · 2013Article
- The rebel angel: mutant p53 as the driving oncogene in breast cancer.Carcinogenesis · 2012Review
- Characterization of bioactive recombinant human lysozyme expressed in milk of cloned transgenic cattle.PloS one · 2011Article
- Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.Cancer gene therapy · 2011Review
- Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system.PloS one · 2010Article
- Recent advances in p53 research: an interdisciplinary perspective.Cancer gene therapy · 2009Review
- Peptides from the SARS-associated coronavirus as tags for protein expression and purification.Protein expression and purification · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the construction and phenotypic characterization of 23 whey acidic protein (WAP)-mutp53 transgenic mouse lines. The mutp53-expressing lines showed a mosaic expression pattern for the transgenes, leading to a heterogeneous yet mouse line-specific expression pattern for mutp53 upon induction. Only few lines were obtained, in which the majority of the induced mammary epithelial cells expressed the mutp53 transgene, most of the transgenic lines did not express mutp53, or expressed the transgene in less than 2% of the induced mammary epithelial cells. Hormone requirements for mutp53 transgene expression from the WAP-promoter differed in high and low expressing lines, being low in high expressing lines, and even lower in multiparous mutp53 mice, where persistent expression of the transgene occurred. Repeated induction of mutp53 expression through repeated parturition resulted in the formation of expanding mutp53-expressing foci within the mammary alveolar epithelium. The data suggest that epigenetic mechanisms play a role in modulating the expression of the mutp53 transgene. To support this idea, we crossed a nonexpressing WAP-mutp53 line with a strongly SV40 T-antigen-expressing WAP-T mouse line. In the bitransgenic mice, T-antigen-induced chromatin remodeling led to re-expression of epigenetically silenced mutp53 transgene(s). In these mice, mutp53 expression was much more variable compared to SV40 T-antigen expression, and seemed to depend on the coexpression of SV40 T-antigen. Mutp53 expression in this system thus resembles the situation in many human tumors, where one can observe a heterogeneous expression of mutp53, despite a homogeneous distribution of the p53 mutation in the tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.